Home > Knowledge > Content
Sep 20, 2017

Lenalidomide is a thalidomide analog that has immunomodulatory, anti-angiogenic and anti-tumor properties. In  multiple myeloma cells, lenalidomide and dexamethasone synergies, can  inhibit cell proliferation, leading to tumor cell apoptosis. The  drug is used in combination with dexamethasone for use in the treatment  of multiple myeloma (MM); it can also be used to treat patients who  have received at least one therapy because of a low risk of 5q  chromosome deletion, presence or absence of other cytogenetic  abnormalities Or moderate-1 risk of  myelodysplastic syndromes (MSD), as well as for the treatment of  recurrent and progressive mantle cell lymphomas that have received two  treatments that have received a bortezomib therapy (MCL).

Previous: Pharmacology and pharmacokinetics

Next: No Information